Obesity is the fastest-growing indication segment, driven by high-efficacy weight loss data, expanded regulatory approvals, and direct-to-consumer demand [1]
They are fundamentally different classes of peptides working on different receptor pathways Their combination (CagriSema) delivered 22.7% mean weight loss at 68 weeks vs 16.1% for Semaglutide alone and 11.8% for Cagrilintide alone in the REDEFINE 1 trial In type 2 diabetics, CagriSema achieved 13.7% weight loss vs 3.4% with placebo at 68 weeks The side effects of CagriSema are comparable to semaglutide alone, though GI events and injection site reactions are somewhat higher with the combination What Most People Get Wrong About Cagrilintide vs Semaglutide First, lets clear up the fundamental confusion thats plaguing this entire conversation
Whether taken by pill or injection, GLP-1 drugs can be a life-changing treatment for people with type 2 diabetes and/or obesity
However, these agents are associated with increased thyroid cancer risk, and the packaging for these medications in the United States has a boxed warning stating that they are contraindicated in people with a personal or family history of medullary thyroid cancer and in patients with a diagnosis of multiple endocrine neoplasia syndrome type 2
DCCT sub-analyses established that glycemic variability (not just HbA1c) predicts diabetic complication risk, making pramlintide's variability-reducing effects potentially more clinically important than the modest HbA1c change alone
